Author + information
- Ashley Beecy,
- Donghee Han,
- Bríain Ó. Hartaigh,
- Khalil Anchouche,
- Subhi Al'Aref,
- Heidi Gransar,
- Ji Hyun Lee,
- Mahn Won Park,
- Hadi Mirhedayati Roudsari,
- Asim Rizvi,
- Fay Lin,
- James Min and
- Jessica M. Peña
Background: In clinical practice, asymptomatic patients may be referred for evaluation by coronary computed tomographic angiography (CCTA), and a portion present with non-obstructive coronary artery disease (CAD). Currently, it is not clear how to synthesize this information with estimated risk using the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score.
Methods: Utilizing the CONFIRM Registry, 503 asymptomatic statin naïve patients with 5-year follow-up were examined. Patients were categorized by CAD severity as determined by CCTA, and graded as none (0%), non-obstructive (1-49%), and obstructive (≥50%). Those with non-obstructive CAD were further characterized by ASCVD risk score as well as major adverse cardiac events (MACE), which comprised all-cause death, non-fatal myocardial infarction, and late coronary revascularization >90 days.
Results: Of the study sample, 222 (44.1%) patients presented with non-obstructive CAD. Of these, 32%, 48.6%, and 19.4% were assigned an ASCVD risk score of <7.5%, 7.5-20%, and >20%, respectively. Notably, the cumulative incidence of MACE increased monotonically according to ASCVD risk score groups (see Figure).
Conclusions: The predicted risk of cardiovascular disease by ASCVD risk score is fitting with the observed risk of MACE in asymptomatic patients with non-obstructive coronary artery disease by CCTA. This observation reinforces recommendations for statin therapy in the current guidelines.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Cardiovascular Risk Assessment and Reduction
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1235-062
- 2017 American College of Cardiology Foundation